Ongoing proof-of-concept (PoC) clinical trial in pain associated with pancreatic cancer with topline data on track for 1H 2025

Conduit Pharmaceuticals partners with Charles River to evaluate the efficacy of its lead programme in a pre-clinical lupus model, utilizing Charles River's immunology expertise to refine study parameters and improve probability of successful Phase II clinical trial outcomes. The study aims to accelerate the development of AZD1656 (and its derivatives), for autoimmune disorders, with a focus on Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN).

Research Published in the Prestigious Journal of Cardiac Failure From Three Institutions Oak Ridge, TN, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a multicenter study published in the prestigious Journal of Cardiac Failure reporting pivotal insights for effective heart failure treatment through the use of Daxor's Blood Volume Analysis (BVA). The study demonstrates how BVA outperforms standard hemodynamic measurements in assessing heart failure volume status, while highlighting its unique capability to detect anemia, a crucial factor for effective treatment.

BOCA RATON, Fla., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Red Violet, Inc. (NASDAQ: RDVT), a leading analytics and information solutions provider, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2024 after the close of the U.S. financial markets on Thursday, February 27, 2025.

I am upgrading NUE shares to a BUY rating with a price target of $152/share, driven by supportive tariffs and strong market outlooks across key industries. Nucor may not be significantly impacted by tariffs as most of its steel exports are high-value-added products as opposed to commoditized steel. Nucor's long-term growth may be supported by multiple megatrends, including nearshoring, data center construction, and power transmission.

Completion of SON-1010 (IL12-F H AB) monotherapy dose escalation in Phase 1 SB101 trial; Stable disease (SD) at four months post-initiation of dosing was seen in 48% evaluable monotherapy patients, and one patient dosed at the MTD, resulting in a partial response (PR)

Recurring revenue growth from partners exceeds $35,000 per month after a few weeks $25,000 in monthly cost reductions anticipated after converting salaried sales staff to Partners program Scalable-location based digital marketing solution appeals to multi-location businesses PERTH, Australia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Locafy Limited (Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a globally recognized leader in location based digital marketing solutions, with market leading SEO capabilities, today announced the launch of Localizer, a powerful solution designed to help businesses improve their online visibility and rank higher in local search results. With 46% of Google searches seeking local products …

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that, per the charter of the trial's independent Data Safety Monitoring Board (DSMB), the Company has initiated the assembly of an outside expert panel to review unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).

ATLANTA , Feb. 13, 2025 /PRNewswire/ -- Reply, a global systems integrator and technology firm, is proud to announce the launch of Comwrap Reply in North America. This strategic expansion builds on Comwrap Reply's inception in 2004 and established presence in Germany, Italy, and the UK, enhancing its position as a leading provider of AI-powered, end-to-end digital experience solutions.

GDEV Inc. announces the appointment of Andrey Fadeev, GDEV's founder and CEO and a member of the Company's Board of Directors, as Chairperson of the Board.

SUSSEX, Wis. , Feb. 13, 2025 /PRNewswire/ -- Quad/Graphics, Inc. (NYSE: QUAD) ("Quad" or the "Company"), a global marketing experience company, announced today that its Board of Directors approved an increase in the quarterly dividend on the Company's common stock from $0.05 per share, or $0.20 per share on an annualized basis, to $0.075 per share, or $0.30 per share on an annualized basis.

Financial Highlights Audio Division Record Revenue: $90.6M, +13% YoY; Q3 Fiscal 2025 Revenue: $27.1M Audio Division YTD Adjusted EBITDA*: $14.1M; Q3 Fiscal 2025: $3.6M Additional $44M in Contracted Revenue and B2B Deals Closed 5 B2B Deals, Expects to Close 2+ by Year-End, with 70+ in Pipeline 800K Tesla Subscribers, Including 475K+ Ad-Supported, Added 100k+ Following Presentation at Trump's Mar-a-Lago Cash: $10.9M as of Dec. 31, 2024 Cost Savings via Restructurings: $11M $12M Buyback Program Reaffirmed, with $6.2M Remaining PodcastOne (Nasdaq: PODC) LVO Owns ~72% of PodcastOne (Nasdaq: PODC) Acquired 342,000 PODC Shares this Quarter, Totaling 925,000 PODC Shares to Date …

Portage, Michigan, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day on Thursday, February 27, 2025 at Citigroup Headquarters, New York, New York.

VANCOUVER, British Columbia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions, announces that its subsidiary ZenaDrone has developed and is currently testing a proprietary drone communications management system called “DroneNet” that enables direct and secure drone communications in situations without reliable internet, cellular or satellite communications. The internally developed system is specifically built for use with the Company's ZenaDrone 1000 and IQ series of drone products.

STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that it will report fourth quarter and full-year 2024 financial results after the market closes on Thursday, February 27, 2025. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

New York, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Kaltura (Nasdaq: KLTR), the Video Experience Cloud, today announced that it has been recognized as a Representative Vendor in the Gartner Market Guide for Meeting Solutions. Kaltura's AI-infused, real-time-conferencing experience component, Kaltura Room, powers a wide array of synchronous meeting experiences, from marketing, sales, and customer success to teaching, learning, training, certification, corporate communication, collaboration, and more.

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V.

MONTREAL , Feb. 13, 2025 /PRNewswire/ - Lightspeed Commerce Inc. (NYSE: LSPD) (TSX: LSPD) ("Lightspeed" or the "Company"), today released the registration and attendance information for its Capital Markets Day at the New York Stock Exchange on Wednesday, March 26, 2025. Lightspeed is the unified POS and payments platform for ambitious entrepreneurs to accelerate growth, provide the best customer experiences and become a go-to destination in their space.

DALLAS and TYSONS, Va., Feb. 13, 2025 (GLOBE NEWSWIRE) -- The Dallas Wings and TEGNA's (NYSE: TGNA) KFAA in Dallas have announced a landmark broadcast rights agreement, making the station the exclusive local television partner of the Dallas Wings.